Role of docetaxel in the treatment of advanced gastric carcinoma

Role of docetaxel in the treatment of advanced gastric carcinoma

Authors

  • Mario Scartozzi Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Ancona
  • Eva Galizia U.O. Oncologia Medica, Fabriano
  • Maristella Bianconi Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Ancona
  • Rossana Berardi Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Ancona
  • Stefano Cascinu Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Università Politecnica delle Marche, Ancona

DOI:

https://doi.org/10.7175/cmi.v3i1.557

Keywords:

Gastric carcinoma, Stomach, Docetaxel, DCF schedule

Abstract

With a median survival of 9-11 months, advanced gastric cancer represents one of the most aggressive neoplastic disease in western Countries. Radical surgery is considered the cornerstone for any curative procedure, however only a relatively small proportion of resected cases can be considered cured after surgery. In the last few years research data suggested that advanced gastric cancer can be classified into 2 distinct clinical categories: locally advanced (nonmetastatic, non resectable) and metastatic. While the therapeutic goal in the metastatic setting is palliation and survival improvement, in locally advanced cases one of the main goals of the treatment should be response with the aim to make resectable what was unresectable. The introduction of docetaxel for the treatment of advanced gastric cancer represented then a crucial step forward for the cure of this disease with an improvement in both survival and response rate. In this article we reviewed past and ongoing trials using docetaxel in gastric cancer with the aim to delineate a possible effective strategy for the treatment of this tumour

Downloads

Published

2009-03-15

Issue

Vol. 3 No. 1 (2009)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)